{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:27:40Z","timestamp":1793582860507,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"HK inno.N Corp."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40262-023-01228-4","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T17:36:39Z","timestamp":1679852199000},"page":"599-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole"],"prefix":"10.1007","volume":"62","clinical-trial-number":[{"clinical-trial-number":"nct04568772","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eunsol","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Chun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-9194","authenticated-orcid":false,"given":"SeungHwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"issue":"4","key":"1228_CR1","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","volume":"162","author":"LE Targownik","year":"2022","unstructured":"Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162(4):1334\u201342.","journal-title":"Gastroenterology"},{"issue":"8","key":"1228_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/11531320-000000000-00000","volume":"49","author":"R Ogawa","year":"2010","unstructured":"Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49(8):509\u201333.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1228_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","volume":"37","author":"R-S Wedemeyer","year":"2014","unstructured":"Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201\u201311.","journal-title":"Drug Saf"},{"issue":"2","key":"1228_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40262-014-0230-6","volume":"54","author":"X-L Jiang","year":"2015","unstructured":"Jiang X-L, Samant S, Lesko LJ, Schmidt S. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015;54(2):147\u201366.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1228_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2165\/00003088-200140070-00004","volume":"40","author":"T Andersson","year":"2001","unstructured":"Andersson T, Hassan-Alin M, Hasselgren GR, R\u00f6hss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40(7):523\u201337.","journal-title":"Clin Pharmacokinet"},{"issue":"14","key":"1228_CR6","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.jacc.2011.12.024","volume":"59","author":"AL Frelinger 3rd","year":"2012","unstructured":"Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1228_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00002018-200629090-00002","volume":"29","author":"H Blume","year":"2006","unstructured":"Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29(9):769\u201384.","journal-title":"Drug Saf"},{"issue":"6","key":"1228_CR8","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.01.011","volume":"27","author":"ER Przespolewski","year":"2018","unstructured":"Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the effect of six proton pump inhibitors on the antiplatelet effects of clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582\u20139.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"8","key":"1228_CR9","first-page":"939","volume":"22","author":"MA Serbin","year":"2016","unstructured":"Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-proton pump inhibitor drug-drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. J Manag Care Spec Pharm. 2016;22(8):939\u201347.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1228_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5056\/jnm18029","volume":"24","author":"T Oshima","year":"2018","unstructured":"Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24(3):334\u201344.","journal-title":"J Neurogastroenterol Motil."},{"issue":"2","key":"1228_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s13318-018-0521-7","volume":"44","author":"M Nishihara","year":"2019","unstructured":"Nishihara M, Yamasaki H, Czerniak R, Jenkins H. In vitro assessment of potential for CYP-inhibition-based drug-drug interaction between vonoprazan and clopidogrel. Eur J Drug Metab Pharmacokinet. 2019;44(2):217\u201327.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"7","key":"1228_CR12","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/bcp.13914","volume":"85","author":"R Funakoshi","year":"2019","unstructured":"Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454\u201363.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1228_CR13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/cpt.863","volume":"103","author":"T Kagami","year":"2018","unstructured":"Kagami T, Yamade M, Suzuki T, Uotani T, Hamaya Y, Iwaizumi M, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype. Clin Pharmacol Ther. 2018;103(5):906\u201313.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1228_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/apt.15438","volume":"50","author":"S Han","year":"2019","unstructured":"Han S, Choi HY, Kim YH, Nam JY, Kim B, Song GS, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, healthy male subjects. Aliment Pharmacol Ther. 2019;50(7):751\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1228_CR15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.clinthera.2022.06.002","volume":"44","author":"SJ Moon","year":"2022","unstructured":"Moon SJ, Shin N, Kang M, Kim B, Kim MG. Pharmacokinetic interactions between tegoprazan and naproxen, aceclofenac, and celecoxib in healthy Korean male subjects. Clin Ther. 2022;44(7):930-44.e1.","journal-title":"Clin Ther"},{"key":"1228_CR16","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION: MALARONE (atovaquone and proguanil hydrochloride) tablets. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021078s023lbl.pdf. Accessed 29 Oct 2022."},{"key":"1228_CR17","unstructured":"Guidance for Industry: Clinical Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. 2020. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) https:\/\/www.fda.gov\/media\/134581\/download. Accessed 13 Feb 2023."},{"issue":"9\u201310","key":"1228_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s002280000206","volume":"56","author":"M Hassan-Alin","year":"2000","unstructured":"Hassan-Alin M, Andersonn T, Bredberg E, R\u00f6hss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol. 2000;56(9\u201310):665\u201370.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1228_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18","volume":"6","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Nishimura A, Kennedy G, Hibberd M, Jenkins R, Okamoto H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese\/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6(6): e94.","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"1228_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2174\/138920008784746382","volume":"9","author":"J Yang","year":"2008","unstructured":"Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, et al. Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions. Curr Drug Metab. 2008;9(5):384\u201394.","journal-title":"Curr Drug Metab"},{"issue":"6","key":"1228_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/clpt.2013.167","volume":"94","author":"N Inui","year":"2013","unstructured":"Inui N, Akamatsu T, Uchida S, Tanaka S, Namiki N, Karayama M, et al. Chronological effects of rifampicin discontinuation on cytochrome P450 activity in Healthy Japanese volunteers, using the cocktail method. Clin Pharmacol Ther. 2013;94(6):702\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1228_CR22","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","volume":"94","author":"J Hakkola","year":"2020","unstructured":"Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol. 2020;94(11):3671\u2013722.","journal-title":"Arch Toxicol"},{"issue":"1","key":"1228_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/cpt.1128","volume":"105","author":"J Matthaei","year":"2019","unstructured":"Matthaei J, Seitz T, Jensen O, Tann A, Prukop T, Tadjerpisheh S, et al. OCT1 deficiency affects hepatocellular concentrations and pharmacokinetics of cycloguanil, the active metabolite of the antimalarial drug proguanil. Clin Pharmacol Ther. 2019;105(1):190\u2013200.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1228_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1124\/dmd.106.013581","volume":"35","author":"H-J Kang","year":"2007","unstructured":"Kang H-J, Song I-S, Shin HJ, Kim W-Y, Lee C-H, Shim J-C, et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos. 2007;35(4):667\u201375.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"1228_CR25","first-page":"619","volume":"73","author":"B Sienkiewicz-Oleszkiewicz","year":"2018","unstructured":"Sienkiewicz-Oleszkiewicz B, Wiela-Hoje\u0144ska A. CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs. Pharmazie. 2018;73(11):619\u201324.","journal-title":"Pharmazie"},{"issue":"4","key":"1228_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/FTD.0b013e31811f383c","volume":"29","author":"SS Lee","year":"2007","unstructured":"Lee SS, Lee SJ, Gwak J, Jung HJ, Thi-Le H, Song IS, et al. Comparisons of CYP2C19 genetic polymorphisms between korean and vietnamese populations. Ther Drug Monit. 2007;29(4):455\u20139.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1228_CR27","first-page":"4195","volume":"17","author":"M Dehbozorgi","year":"2018","unstructured":"Dehbozorgi M, Kamalidehghan B, Hosseini I, Dehghanfard Z, Sangtarash M, Firoozi M, et al. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (-806 C>T) alleles among an Iranian population of different ethnicities. Mol Med Report. 2018;17(3):4195\u2013202.","journal-title":"Mol Med Report."},{"issue":"4","key":"1228_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/0035-9203(90)90010-C","volume":"84","author":"WM Watkins","year":"1990","unstructured":"Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, Koech DK. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg. 1990;84(4):492\u20135.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1228_CR29","unstructured":"Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers. 2022. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed 29 Oct 2022."},{"key":"1228_CR30","first-page":"068","volume":"5","author":"L Geng","year":"2019","unstructured":"Geng L, Han L, Huang L, Wu Z, Wu Z. High anti-acid omeprazole lightweight capsule for gastro-enteric system acid-related disorders treatment. J Clin Gastroenterol Treat. 2019;5:068.","journal-title":"J Clin Gastroenterol Treat."},{"issue":"2","key":"1228_CR31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ijpharm.2013.06.034","volume":"453","author":"C Wu","year":"2013","unstructured":"Wu C, Sun L, Sun J, Yang Y, Ren C, Ai X, et al. Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology. Int J Pharm. 2013;453(2):300\u20136.","journal-title":"Int J Pharm"},{"issue":"7","key":"1228_CR32","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.xphs.2018.03.009","volume":"107","author":"GF Pl\u00f6ger","year":"2018","unstructured":"Pl\u00f6ger GF, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Mehta MU, et al. Biowaiver monographs for immediate release solid oral dosage forms: proguanil hydrochloride. J Pharm Sci. 2018;107(7):1761\u201372.","journal-title":"J Pharm Sci"},{"issue":"6","key":"1228_CR33","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1128\/AAC.41.6.1319","volume":"41","author":"PE Rolan","year":"1997","unstructured":"Rolan PE, Mercer AJ, Tate E, Benjamin I, Posner J. Disposition of atovaquone in humans. Antimicrob Agents Chemother. 1997;41(6):1319\u201321.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1228_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00228-002-0426-9","volume":"58","author":"MM Thapar","year":"2002","unstructured":"Thapar MM, Ashton M, Lindeg\u00e5rdh N, Bergqvist Y, Nivelius S, Johansson I, et al. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol. 2002;58(1):19\u201327.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1228_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s002280050634","volume":"55","author":"C Gillotin","year":"1999","unstructured":"Gillotin C, Mamet JP, Veronese L. Lack of a pharmacokinetic interaction between atovaquone and proguanil. Eur J Clin Pharmacol. 1999;55(4):311\u20135.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01228-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01228-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01228-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T01:26:53Z","timestamp":1681090013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01228-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01228-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"15 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by HK inno.N Corp., Seoul, Republic of Korea.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol and informed consent form of this study were reviewed and approved by the Ministry of Food and Drug Safety of Korea and by the Institutional Review Board at Seoul National University Hospital. This study was performed in accordance with the Korean Good Clinical Practice guidelines and the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written consent was obtained from each subject prior to any study-related procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The individual de-identified participant data supporting published results are available with approval from the corresponding author on reasonable request, at any time after publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"YE and LS wrote the manuscript. YE and LS designed the research. YE, SCJ, I-JJ, and LS performed the research. YE and LS analyzed the data. All the authors reviewed and revised the paper. All the authors approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}